MX-2401

MX-2401 is a semisynthetic calcium-dependent lipopeptide antibiotic and an analogue of amphomycin. It was primarily developed for the treatment of serious Gram-positive bacterial infections, including antibiotic-resistant strains such as methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). Its mechanism of action involves inhibiting peptidoglycan synthesis by binding to undecaprenylphosphate (C55-P), the universal carbohydrate carrier involved in several biosynthetic pathways. This interaction results in the dose-dependent inhibition of cell wall precursors Lipid I and Lipid II, as well as wall teichoic acid. Unlike daptomycin, MX-2401 does not target the bacterial membrane and retains activity in the presence of lung surfactant, suggesting potential efficacy in pulmonary infections such as pneumonia.